Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
How Restrictive are NICE ‘Optimised’ Decisions?
27 April 2023
NICE makes ‘optimised’ decisions to support use of medicines in smaller groups of patients. Between 2020 to 2022, 56% of optimised decisions recommended treatment for less than half of eligible patients.
Around The World in HTAs: Italy – What’s Next?
20 April 2023
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Claudio Jommi, Università del Piemonte Orientale Novara, and Martina Garau, OHE, take us to Italy.
Caring about Carers: Improving Consideration of the Burden of Informal Caring in HTA
11 April 2023
Through a three-part webinar series, commissioned and funded by Roche, OHE has explored the burdens on informal carers when providing unpaid care for loved ones.
Around The World in HTAs: Spain – Are We There Yet?
15 March 2023
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Laura Vallejo-Torres, University of Las Palmas de Gran Canaria, and Patricia Cubi-Molla, OHE, take us to Spain.
Informal Caring Burden in HTA Series: Webinar 3 – Capturing carer burden in HTA: what is the future?
2 March 2023
In this three-part webinar series, commissioned and funded by Roche, we explore the incorporation of informal care in HTA.
Informal Caring Burden in HTA Series: Webinar 2 – How is carer burden captured in HTA, and what are some of the existing challenges?
27 February 2023
In this three-part webinar series, commissioned and funded by Roche, we explore the incorporation of informal care in HTA.
Informal Caring Burden in HTA Series: Webinar 1 – What is carer burden and why is it important in HTA?
22 February 2023
In this three-part webinar series, commissioned and funded by Roche, we explore the incorporation of informal care in HTA.
Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?
15 February 2023
Gene therapies pose fresh challenges for discounting practice by HTA agencies. In this blog, we discuss why discounting is important for gene therapies, using a potential gene therapy for X-Linked Retinitis Pigmentosa (XLRP) as an example.
ISPOR Europe Round-up: “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?”
8 December 2022
OHE, in collaboration with Pfizer, hosted an educational symposium entitled “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA methodologies Appropriately Value and Enable Access?”.